

This interim analysis indicated that there is no benefit from imaging in the follow-up programme for individuals with high-risk cutaneous malignant melanoma. However, only a few participants have completed the follow-up time of 5 years, and the numerical difference between the study groups in distant metastasis-free survival motivates us to continue the study according to protocol.
Oncology
|31st Dec, 2025
|Journal of the American Medical Association
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet
Oncology
|15th Jan, 2026
|The Lancet